Page contents Key factsDecisionRelated medicine informationKey facts Invented name Cosentyx Active Substance Secukinumab Therapeutic area Immunology-Rheumatology-Transplantation Decision number P/0560/2021 PIP number EMEA-000380-PIP08-21 Pharmaceutical form(s) Powder for solution for injectionSolution for injection Condition(s) / indication(s) Treatment of vasculitides Route(s) of administration Subcutaneous use Contact for public enquiries Novartis Europharm LimitedE-mail: paediatric.enquiries@novartis.comTel. +41 6132 41111 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 03/12/2021DecisionP/0560/2021 : EMA decision of 31 December 2021 on the granting of a product specific waiver for secukinumab (Cosentyx), (EMEA-000380-PIP08-21)AdoptedReference Number: EMA/649533/2021 English (EN) (142.15 KB - PDF)First published: 02/03/2023ViewRelated medicine informationCosentyxShare this page